When was Halda Therapeutics founded?

Halda Therapeutics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Halda Therapeutics located?

Halda Therapeutics is headquartered in New Haven, United States.

Who is the current CEO of Halda Therapeutics?

Craig Crews of Halda Therapeutics. They have also founded 2 companies.

Is Halda Therapeutics a funded company?

Halda Therapeutics is a funded company, having raised a total of $217M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 28, 2019.

How much is Halda Therapeutics worth?

The last known valuation of Halda Therapeutics was $***** as of Nov 17, 2025.

When was the latest funding round of Halda Therapeutics?

Halda Therapeutics' latest funding was a $***** Series B round on Aug 12, 2024, with participation from 10 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.68B in funding in 2026 to date.

Where does Halda Therapeutics rank among its competitors?

Halda Therapeutics ranks 53rd amongst 3423 active competitors, of which 1128 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Halda Therapeutics?

Halda Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Halda Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Halda Therapeutics is an acquired company based in New Haven (United States), founded in 2019 by Craig Crews. It operates as a Developer of precision therapeutics for cancer treatment. Halda Therapeutics has raised $217M in funding from investors like Connecticut Innovations, Elm Street Ventures and Canaan, with last known valuation of $*****. The company has 3423 active competitors, including 1128 funded and 788 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of precision therapeutics for cancer treatment. It offers a lead drug candidate which is a RIPTAC therapeutic that utilizes androgen receptor as a targeting protein to selectively deliver the drug for the treatment of metastatic, castrate-resistant prostate cancer, and tumors.

Website: haldatx.com
Social
Email ID: *****@haldathera.com
Phone Number: +1 **********

Key Metrics

Founded Year

2019

Location

New Haven, United States

Stage

Acquired

Total Funding

$217M in 4 rounds

Latest Funding Round

Series B, Aug 12, 2024, $*****

Last Known Valuation

$***** as on Nov 17, 2025

Investors

Connecticut Innovations & 11 more

Ranked

53^rd among 3423 active competitors

Similar Companies

Jazz Pharmaceuticals & 3029 more

Exit Details

Acquired by Johnson & Johnson (Nov 17, 2025)

View Halda Therapeutics' full profile

Halda Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
HALDA THERAPEUTICS INC. CIN: 832428365 , United States, Active		-	-	-

Halda Therapeutics got acquired by Johnson & Johnson on Nov 17, 2025 at an acquisition amount of $*****.

Click here to take a look at Halda Therapeutics's acquisition in detail

Halda Therapeutics has raised a total funding of $217M over 4 rounds. Its first funding round was on Feb 28, 2019. Its latest funding round was a Series B round on Aug 12, 2024 for $*****. 10 investors participated in its latest round. Halda Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of Halda Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 12, 2024	3982443	Series B	9111666	4611602	4700278	4390958
May 21, 2024	2442731	Series B	1035404	6016634	6801057	7905541
Dec 09, 2021	2493518	Series B	1481744	8949291	Access Biotechnology	6790832

Access funding benchmarks and valuations. Sign up today!

View details of Halda Therapeutics's funding rounds and investors

The founders of Halda Therapeutics is Craig Crews. Craig Crews is the CEO of Halda Therapeutics.

Here are the details of Halda Therapeutics' key team members:

Craig Crews: Founder & CEO of Halda Therapeutics and founder of 1 other company.
Contact Info: 1 email address

View details of Halda Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Halda Therapeutics include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Halda Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
53rd	Halda Therapeutics 2019, New Haven (United States), Acquired	Developer of precision therapeutics for cancer treatment	$217M	Access Industries, Boxer Capital & 10 others	65/100